Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06130995 · ClinicalTrials.gov registry record · Phase 1

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

A Phase 1 study of Androgen Deprivation Therapy and Locally Advanced Prostate Cancer, sponsored by University of Oklahoma.

Recruiting
Registry status
Phase 1
Development phase
46
Enrollment target
1
Study location

NCT06130995 is a Phase 1 study of Androgen Deprivation Therapy and Locally Advanced Prostate Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 46 participants, roughly in line with the 43-participant average among 5 other Androgen Deprivation Therapy trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06130995, a Phase 1 study of Androgen Deprivation Therapy and Locally Advanced Prostate Cancer, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Phase 1
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: * Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? * Does this combination treatment help patients live longer without their cancer getting worse? Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.

Conditions Studied

Androgen Deprivation Therapy Locally Advanced Prostate Cancer

Interventions

  • DRUG Relugolix and Enzalutamide

Study Locations (1)

Oklahoma

  • Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC) - Oklahoma City

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2024-12-26
Est. Completion 2030-01
Phase Phase 1

Sponsor

University of Oklahoma

358 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06130995

The ClinicalTrials.gov registry entry for NCT06130995 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 43-participant average among 5 other Androgen Deprivation Therapy trials with a reported enrollment target. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Androgen Deprivation Therapy appearing as the primary indexed condition, and to 1 intervention - of which Relugolix and Enzalutamide is the first listed.

NCT06130995 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT06130995 about?

NCT06130995 is a clinical study titled "Relugolix + Enzalutamide Study in High-Risk Prostate Cancer". The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live long...

What is the current status of trial NCT06130995?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-12-26. Estimated completion is 2030-01.

What conditions does trial NCT06130995 study?

This clinical trial studies the following conditions: Androgen Deprivation Therapy, Locally Advanced Prostate Cancer.

What interventions are being tested in trial NCT06130995?

The interventions under investigation include: Relugolix and Enzalutamide (DRUG).

Who is sponsoring clinical trial NCT06130995?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06130995 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Androgen Deprivation Therapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Androgen Deprivation Therapy

All registered trials for this condition

Locally Advanced Prostate Cancer

All registered trials for this condition

Oklahoma

All trials with a study site in Oklahoma

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.